Jesús Medina, Alicia G. Arroyo, Francisco Sánchez‐Madrid, Ricardo Moreno‐Otero – 26 April 2004 – Intrahepatic hypoxia may occur during the inflammatory and fibrotic processes that characterize several chronic liver diseases of viral and autoimmune origin. As a consequence, new vascular structures are formed to provide oxygen and nutrients. Angiogenesis involves a tightly regulated network of cellular and molecular mechanisms that result in the formation of functional vessels.

Guruprasad P. Aithal, Lesley Ramsay, Ann K. Daly, Nhareet Sonchit, Julian B. S. Leathart, Graeme Alexander, J. Gerald Kenna, John Caldwell, Christopher P. Day – 26 April 2004 – Diclofenac is a nonsteroidal anti‐inflammatory drug that causes rare but serious hepatotoxicity, the mechanism of which is unclear. The purpose of the present study was to explore the potential role played by the immune processes.

Jason M. Hui, Geoffrey C. Farrell, James G. Kench, Jacob George – 26 April 2004

Flavia Bortolotti, Maria Guido, Lucia Zancan, Nadia Gussetti – 26 April 2004

Paul C. Adams, Michael J. Arthur, Thomas D. Boyer, Laurie D. DeLeve, Adrian M. Di Bisceglie, Mark Hall, Theodore R. Levin, Dawn Provenzale, Leonard Seeff – 26 April 2004 – This report summarizes an AASLD Clinical Workshop that was presented at Digestive Diseases Week 2003 on screening in liver diseases. As newer diagnostic tests become available, many liver diseases and complications of liver disease can be detected at an early asymptomatic stage. In many cases, early detection can lead to earlier treatment and an improved outcome.

26 April 2004

Alessandro Zanetti, Maria Antonietta Casiraghi – 26 April 2004

Federico Villamil, Stephen Pollard – 20 April 2004 – Adjusting cyclosporine (CsA) dose based on blood concentration at 2 hours after dose (C2) has been shown in prospective clinical trials to reduce the risk of rejection compared with conventional trough monitoring. In addition, it provides equivalent efficacy to tacrolimus in liver transplant patients, with a favorable safety profile. Target C2 should be defined on an individual basis depending on adjunctive therapy and the level of exposure required.

Guy W. Neff, Christopher B. O'Brien, Robert Cirocco, Marzia Montalbano, Maria de Medina, Phillip Ruiz, Amr S. Khaled, Pablo A. Bejarano, Kamran Safdar, Mary A. Hill, Andreas G. Tzakis, Eugene R. Schiff – 20 April 2004 – The optimal duration of therapy for pegylated interferon combined with ribavirin in recurrent Hepatitis C virus (HCV) following liver transplantation is not known.

Valeria R. Mas, Daniel G. Maluf, Richard Stravitz, Catherine I. Dumur, Bradly Clark, Cheryl Rodgers, Andrea Ferreira‐Gonzalez, Robert A. Fisher – 20 April 2004 – Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer death in the world. The present study aimed to investigate the genes involved in viral carcinogenesis and tumor progression in liver transplant recipients with hepatitis C virus (HCV) and HCC.